Fideuram Asset Management Ireland dac Makes New Investment in Edwards Lifesciences Corporation $EW

Fideuram Asset Management Ireland dac purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,713 shares of the medical research company’s stock, valued at approximately $572,000.

A number of other institutional investors also recently bought and sold shares of the business. Level Four Advisory Services LLC lifted its holdings in Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after buying an additional 119 shares during the last quarter. Colonial Trust Co SC lifted its holdings in Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after buying an additional 120 shares during the last quarter. Evermay Wealth Management LLC lifted its holdings in Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after buying an additional 128 shares during the last quarter. Howard Capital Management Inc. lifted its holdings in Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after buying an additional 132 shares during the last quarter. Finally, Florida Trust Wealth Management Co lifted its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after buying an additional 132 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.5%

EW opened at $86.41 on Friday. The business’s 50-day simple moving average is $81.73 and its 200-day simple moving average is $83.01. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $88.28. The stock has a market capitalization of $49.76 billion, a P/E ratio of 45.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, UBS Group reiterated a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $95.65.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,397 shares of company stock valued at $8,848,664 in the last quarter. 0.31% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.